Generate:Biomedicines

Company facts

• Founded

  2018

  ConfirmedSource for founded (opens in new tab)

• Headquarters

  United States (Somerville, MA)

  ConfirmedSource for headquarters (opens in new tab)

Latest funding round

Drug discovery partners

1 pharma, 1 other. Pharma here means a company with approved products and roughly $1B or more in annual revenue.

• Novartis Pharma

  Multi-target collaboration, Sep 24, 2024

  $65M upfront ($1.06B total potential)

  ConfirmedSource for Novartis (opens in new tab)

• Zealand Pharma Biotech

  Collaboration and license, Oct 13, 2026

  $30M upfront ($1.2B total potential)

  ConfirmedSource for Zealand Pharma (opens in new tab)

Drugs on the board

• GB-4362 (MMAE neutralizer) ›

  Phase 1 registry

  Locally advanced or metastatic urothelial cancer (reducing enfortumab vedotin MMAE toxicity)

  Registry for GB-4362 (MMAE neutralizer) (opens in new tab)

• GB-0669 (anti-SARS-CoV-2 antibody) ›

  Phase 1 registry

  COVID-19 (prevention/treatment)

  Registry for GB-0669 (anti-SARS-CoV-2 antibody) (opens in new tab)

• GB-5267 (MUC16 CAR T) ›

  Phase 1 registry

  Platinum-resistant ovarian cancer

  Registry for GB-5267 (MUC16 CAR T) (opens in new tab)

• GB-0895 ›

  Phase 3 registry

  Severe asthma

  Registry for GB-0895 (opens in new tab)

Recent news

• Oct 15, 2026

  Zealand Pharma deal: $30M upfront for generative AI obesity multispecifics

  ReportedSource (opens in new tab)

• Oct 14, 2026

  Zealand Pharma collaboration and license worth up to $1.2B for AI-designed protein therapeutics in metabolic disease

  ConfirmedSource (opens in new tab)

• Oct 1, 2026

  GB-5267 AI-engineered MUC16 CAR T developed with Roswell Park (official)

  ConfirmedSource (opens in new tab)

• Feb 27, 2026

  Listed on Nasdaq as GENB

  ConfirmedSource (opens in new tab)

• Feb 26, 2026

  IPO (Nasdaq: GENB): $400M

  ConfirmedSource (opens in new tab)